Sep 11, 2026 07:00AM
Sep 10, 2026 04:05PM
Sep 10, 2026 04:05PM
Aug 6, 2026 04:05PM
Jul 22, 2026 03:23AM
Jun 12, 2026 12:45PM
Jun 12, 2026 12:45PM Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Cong
Jun 8, 2026 06:00AM
Jun 8, 2026 06:00AM
May 6, 2026 04:05PM
Mar 12, 2026 04:05PM
Feb 12, 2026 07:30AM
Feb 12, 2026 07:30AM
Dec 24, 2025 06:00AM Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
Dec 24, 2025 06:00AM
Dec 8, 2025 02:52AM
Dec 7, 2025 04:30PM
Nov 12, 2025 04:05PM
Nov 10, 2025 07:30AM
Nov 10, 2025 07:30AM
Nov 3, 2025 09:00AM Lyell to present ronde-cel lymphoma trial data at ASH meeting
Nov 3, 2025 09:00AM
Sep 3, 2025 08:00AM
Sep 3, 2025 08:00AM
Aug 12, 2025 04:05PM
Jun 24, 2025 06:48AM
Jun 23, 2025 05:00PM
Jun 17, 2025 06:31AM Lyell Immunopharma (LYEL) Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314
Jun 17, 2025 06:30AM
May 13, 2025 04:05PM
May 1, 2025 09:00AM
Apr 15, 2025 09:00AM
Apr 15, 2025 09:00AM
Mar 11, 2025 04:05PM
Jan 9, 2025 09:00AM Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference
Dec 9, 2024 09:00PM
Nov 7, 2024 04:05PM
Nov 5, 2024 09:30AM
Oct 24, 2024 04:00PM
Oct 24, 2024 04:00PM
Aug 7, 2024 04:05PM
Jun 26, 2024 07:02AM Lyell Immunopharma (LYEL) Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797
Jun 26, 2024 07:00AM
Feb 28, 2024 04:05PM
Nov 9, 2023 04:05PM
Nov 8, 2022 04:05PM
Nov 8, 2022 04:05PM
Oct 6, 2022 04:05PM
Oct 6, 2022 04:05PM Lyell Immunopharma Announces FDA Clearance of its IND for LYL845, a TIL Product Candidate Enhanced with its Novel Epigenetic Reprogramming Technology for Solid Tumors
Oct 6, 2022 04:05PM

334,271 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All